date:Aug 07, 2014
by the EFSA to be risk-free in humans. These findings have therefore highlighted the problem of determining a safe and tolerable daily dose for BPA.
These new results have contributed to characterising the harmful effects of BPA on the immune system at low levels of exposure and at the ages during which individuals are particularly vulnerable because of their immaturity: the foetus and neonate.
These findings support the decision made by the French authorities as early as 2013 to ban the use o